We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Health (CVS) Beats on Q1 Earnings, Revenues Lag Estimate
Read MoreHide Full Article
Ever bought medicines or cosmetics over the counter? Yes, then you may have walked into one of the 9,800 retail CVS/pharmacy stores of the largest pharmacy healthcare services provider in the U.S.–CVS Health Corporation (CVS - Free Report) . This Rhode Island-based company has more than 900 walk-in medical clinics–CVS/MinuteClinic and currently possesses a customer satisfaction rate of 95%.
Currently, CVS Health has a Zacks Rank #3 (Hold) but that could change following its first quarter 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate remained at $1.39 per share. CVS Health’s adjusted earnings per share of $1.48 outpaced this estimate by 6.5%. On a year-over-year basis, this figure registered a 26.5% growth.
Revenues: CVS Health posted revenues of $45.7 billion up 2.6% y/y. However, it lagged the Zacks Consensus Estimate for revenues of $45.8 billion.
Key Stats: For the first quarter CVS Health’s Pharmacy Services segment revenues increased 3.2% year over year to $32.2 billion, while revenues from Retail/LTC segment increased 5.6% year over year to $20.4 billion.
Major Factors: CVS Health witnessed year-over-year growth in Pharmacy Services Segment on the back of growth in pharmacy network and specialty pharmacy volume as well as brand inflation, partially offset by continued price compression and increased generic dispensing. Also, we are encouraged to note that the company has successfully maintained its growth trend in Retail/LTC segment in the reported quarter. The company has reiterated its full-year 2018 adjusted operating profit growth guidance.
Stock Price: Following the earnings release, share prices gained 4.3% in the pre-market trading session.
Check back later for our full write up on this CVS Health earnings report later!
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
CVS Health (CVS) Beats on Q1 Earnings, Revenues Lag Estimate
Ever bought medicines or cosmetics over the counter? Yes, then you may have walked into one of the 9,800 retail CVS/pharmacy stores of the largest pharmacy healthcare services provider in the U.S.–CVS Health Corporation (CVS - Free Report) . This Rhode Island-based company has more than 900 walk-in medical clinics–CVS/MinuteClinic and currently possesses a customer satisfaction rate of 95%.
Currently, CVS Health has a Zacks Rank #3 (Hold) but that could change following its first quarter 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate remained at $1.39 per share. CVS Health’s adjusted earnings per share of $1.48 outpaced this estimate by 6.5%. On a year-over-year basis, this figure registered a 26.5% growth.
CVS Health Corporation Price and EPS Surprise
CVS Health Corporation Price and EPS Surprise | CVS Health Corporation Quote
Revenues: CVS Health posted revenues of $45.7 billion up 2.6% y/y. However, it lagged the Zacks Consensus Estimate for revenues of $45.8 billion.
Key Stats: For the first quarter CVS Health’s Pharmacy Services segment revenues increased 3.2% year over year to $32.2 billion, while revenues from Retail/LTC segment increased 5.6% year over year to $20.4 billion.
Major Factors: CVS Health witnessed year-over-year growth in Pharmacy Services Segment on the back of growth in pharmacy network and specialty pharmacy volume as well as brand inflation, partially offset by continued price compression and increased generic dispensing. Also, we are encouraged to note that the company has successfully maintained its growth trend in Retail/LTC segment in the reported quarter. The company has reiterated its full-year 2018 adjusted operating profit growth guidance.
Stock Price: Following the earnings release, share prices gained 4.3% in the pre-market trading session.
Check back later for our full write up on this CVS Health earnings report later!
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>